Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
XEXeris Biopharma Holdings, Inc. logo

Xeris Biopharma Holdings, Inc. (XERS)

NASDAQ Global Select · Currency in USD
$10.20 ▼ -0.66 (-6.08%)
At close: Oct 23, 4:00 PM ET. Market closed.
$10.25 ▲ +0.05 (+0.47%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$10.86
Open
$10.85
Day's Range
$10.06 – $10.85
52 Week Range
$5.25 – $11.42
Volume
2,372,225
Avg. Volume
2,272,156
Market Cap
$1.86B
Beta (5Y Monthly)
0.84
PE Ratio (TTM)
--
EPS (TTM)
-$0.10
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$15.00

Profile: Xeris Biopharma Holdings, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
435
CEO
John Shannon

Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate $0.03 · Revenue est. $101.68M
DateEst.Actual
Aug 6, 2026$0.01-$0.18Miss
May 7, 2026-$0.00$0.01Beat
Mar 2, 2026$0.03$0.06Beat
Nov 6, 2025$0.01$0.00Miss
Aug 7, 2025-$0.03-$0.01Beat
May 8, 2025-$0.07-$0.06Beat

Analyst view

Consensus price target
$15.00 ▲ +47.1%
Range $14.00 – $16.00
Rating: Buy
Buy 91% · Hold 9% · Sell 0%

Get free alerts on XERS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.